Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants With Non-Cystic Fibrosis Bronchiectasis (NCFB)

NCT07547436 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07547436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07547436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants With Non-Cystic Fibrosis Bronchiectasis (NCFB)
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Suspended
Start date
June 8, 2026
Completion date
May 11, 2029
Enrollment
70 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non-cystic fibrosis bronchiectasis